CytomX Therapeutics, a US-based biotechnology company, has raised $30m in its series B round from a consortium including Roche Venture Fund.
The round was led by US-based venture capital firm Third Rock Ventures, which earlier in the month closed its second fund above target at $426m, and Switzerland-based drugs company Roche’s corporate venturing division.
CytomX, which develops antibodies, previously raised $5m in its series A from angels, according to news provider VentureWire.